PsO Pipeline Watch: Oral IL-23 Blocker Icotrokinra Produces Significant Skin Clearance in Patients with Scalp and Genital PsO
Icotrokinra, Johnson & Johnson’s investigational oral interleukin(IL)-23 blocker, shows significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis, according to new Phase 3 data presented at the 2025 Society for Investigative Dermatology (SID) Annual Meeting in San Diego, CA.